IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...
Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...
IntelGenx (TSXV:IGX; OTCQB:IGXT) completed its first shipment, consisting of 75,000 CBD filmstrips, to Heritage Cannabis Holdings (CSE:CANN) for the Canadian and Australian markets. The CBD filmstrips were produced at...
IntelGenx (TSXV:IGX; OTCQB:IGXT), a leader in pharmaceutical films, agreed to a strategic partnership with atai Life Sciences to develop treatments for mental health disorders. Under the accord, atai initially will...
The U.S. Patent and Trademark Office granted a notice of allowance for an IntelGenx (TSXV:IGX; OTCQB:IGXT) patent application entitled, “Film Dosage Form with Extended Release Mucoadhesive Particles.” This film...
IntelGenx (TSXV:IGX; OTCQB:IGXT) filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “High Loading Oral Film Formulation.” The patent application covers the incorporation of...